These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9635683)

  • 1. Loss of p53 function in uterine papillary serous carcinoma.
    Kovalev S; Marchenko ND; Gugliotta BG; Chalas E; Chumas J; Moll UM
    Hum Pathol; 1998 Jun; 29(6):613-9. PubMed ID: 9635683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
    Zheng W; Liang SX; Yu H; Rutherford T; Chambers SK; Schwartz PE
    Int J Surg Pathol; 2004 Jul; 12(3):207-23. PubMed ID: 15306933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
    Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
    Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma.
    Schmitz MJ; Hendricks DT; Farley J; Taylor RR; Geradts J; Rose GS; Birrer MJ
    Gynecol Oncol; 2000 Jun; 77(3):439-45. PubMed ID: 10831356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of 14-3-3σ is predictive of poor prognosis for patients with human uterine papillary serous carcinoma.
    Suzuki F; Nagase S; Suzuki K; Oba E; Hiroki E; Matsuda Y; Akahira J; Nishigori H; Sugiyama T; Otsuki T; Yoshinaga K; Takano T; Niikura H; Ito K; Sasano H; Yaegashi N
    Tohoku J Exp Med; 2013 Nov; 231(3):193-9. PubMed ID: 24201220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma.
    Bancher-Todesca D; Gitsch G; Williams KE; Kohlberger P; Neunteufel W; Obermair A; Heinze G; Breitenecker G; Hacker NF
    Gynecol Oncol; 1998 Oct; 71(1):59-63. PubMed ID: 9784320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma.
    King SA; Adas AA; LiVolsi VA; Takahashi H; Behbakht K; McGovern P; Benjamin I; Rubin SC; Boyd J
    Cancer; 1995 Jun; 75(11):2700-5. PubMed ID: 7743473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium.
    Busmanis I; Ho TH; Tan SB; Khoo KS
    Ann Acad Med Singap; 2005 Aug; 34(7):421-5. PubMed ID: 16123814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uterine papillary serous carcinoma evolves via a p53-driven pathway.
    Moll UM; Chalas E; Auguste M; Meaney D; Chumas J
    Hum Pathol; 1996 Dec; 27(12):1295-300. PubMed ID: 8958301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
    Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
    Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma.
    Zheng W; Khurana R; Farahmand S; Wang Y; Zhang ZF; Felix JC
    Am J Surg Pathol; 1998 Dec; 22(12):1463-73. PubMed ID: 9850172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
    Ramondetta L; Mills GB; Burke TW; Wolf JK
    Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
    Nordström B; Strang P; Lindgren A; Bergström R; Tribukait B
    Anticancer Res; 1996; 16(2):899-904. PubMed ID: 8687148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a region on chromosome 1p in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma.
    Herzog TJ; Kowalski LD; Liu H; Arlt M; Swisher E
    Gynecol Oncol; 2001 Jul; 82(1):139-42. PubMed ID: 11426975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and characterization of two cell lines (HEC-155, HEC-180) derived from uterine papillary serous adenocarcinoma.
    Iida T; Hamano M; Yoshida N; Yonamine K; Hayashi K; Kiguchi K; Ishizuka B; Nishimura Y; Arai T; Kawaguchi M; Hata H; Watanabe J; Kuramoto H
    Eur J Gynaecol Oncol; 2004; 25(4):423-7. PubMed ID: 15285295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features.
    Liang SX; Chambers SK; Cheng L; Zhang S; Zhou Y; Zheng W
    Int J Surg Pathol; 2004 Oct; 12(4):319-31. PubMed ID: 15494858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma.
    Idrees MT; Schlosshauer P; Li G; Burstein DE
    Histopathology; 2006 Jul; 49(1):75-81. PubMed ID: 16842248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hysteroscopic and immunohistochemical findings in type I and type II endometrial carcinomas.
    Maia H; Maltez A; Fahel P; Coutinho E
    J Am Assoc Gynecol Laparosc; 2001 May; 8(2):222-30. PubMed ID: 11342729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.